Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splicing factor 3A subunit 2 (SF3A2) is a core protein component of the SF3a complex, essential for spliceosome assembly and pre-mRNA splicing, which is required for removing introns from pre-mRNAs during gene expression. SF3A2 forms part of a heterotrimer with two other subunits and is involved in the conversion of the 15S U2 snRNP into the active 17S particle necessary for splicing. The SF3A2 protein contains a zinc finger domain that mediates RNA binding and interacts with subunit 1 via its amino-terminus. Beyond its canonical role in splicing, SF3A2 is implicated in mitotic chromosome segregation due to its ability to bind microtubules and localize to spindle microtubules. Genetic associations link SF3A2 to susceptibility loci in myocardial infarction, indicating a possible role in cardiovascular disease pathogenesis through alternative functions outside RNA processing. SF3A2 is not currently recognized as a direct therapeutic target, and no drugs are known to act on this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing factor 3A subunit 2 (SF3A2).